Genentech Provides Update on Phase III Study of Onartuzumab in People with Specific Type of Lung Cancer
Wall-Street.com Retains TransMedia Group To Publicize 'Where Money Never Sleeps'
Teva Announces Launch of Generic Xeloda® Tablets 150 MG and 500 MG in the United States
Leadership Announcement and Membership Changes Announced for San Francisco Federal Reserve’s Economic Advisory Council
Genentech DNA continues to focus attention on its commercial lineup, making its slimmer early-stage pipeline not worrisome yet. The biotech firm has additional clinical trials and hopes to expand indications for each of its largest products, including Avastin, Herceptin, and Rituxan. According to ...
Celgene's CELG prized drug Revlimid was approved for multiple myeloma in June, and third-quarter results gave us our first look at sales for its use in treating a second form of blood cancer. While Revlimid's multiple myeloma launch was strong and did not appear to cannibalize legacy drug ...
The five biotech ETFs have very different portfolios with markedly different performance.
While we remain bullish on the sector, health-care growth depends on the economy.